Ambroxol

Generic Name
Ambroxol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C13H18Br2N2O
CAS Number
18683-91-5
Unique Ingredient Identifier
200168S0CL
Background

Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the resp...

Indication

Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.

Associated Conditions
-
Associated Therapies
Airway secretion clearance therapy
Clinical Trials
Related News

Ambroxol as a Treatment for Parkinson's Disease Dementia

Phase 2
Active, not recruiting
Conditions
Parkinson's Disease Dementia
Interventions
Other: Placebo
Drug: Ambroxol
First Posted Date
2016-09-26
Last Posted Date
2024-02-28
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
55
Registration Number
NCT02914366
Locations
🇨🇦

Parkwood Institute, London, Ontario, Canada

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

First Posted Date
2012-04-09
Last Posted Date
2012-07-19
Lead Sponsor
Hanmi Pharmaceutical Company Limited
Target Recruit Count
21
Registration Number
NCT01573663
Locations
🇰🇷

Samsung medical center, Seoul, Korea, Republic of

Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease

Phase 1
Suspended
Conditions
Type I Gaucher Disease
Interventions
Drug: Ambroxol
First Posted Date
2011-11-01
Last Posted Date
2013-02-15
Lead Sponsor
Exsar Corporation
Target Recruit Count
20
Registration Number
NCT01463215
Locations
🇺🇸

ExSAR Corporation, Monmouth Junction, New Jersey, United States

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Phase 3
Completed
Conditions
Pharyngitis
Interventions
Drug: Placebo
Drug: Ambroxol
First Posted Date
2007-09-05
Last Posted Date
2019-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
249
Registration Number
NCT00525044
Locations
🇨🇳

Boehringer Ingelheim Investigational Site, Wuhan, China

🇨🇳

ENT Subsidiary of Fudan University Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy